A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

The Whitrod family launched Genetic Cures for Kids in the hopes of finding a treatment for their daughter with hereditary ...

The biotech will add a pivotal Phase III cohort to its ongoing Phase I/II trial evaluating ATSN-201 in X-linked retinoschisis ...

Based on data from the BEACON and NAUTICAL studies, regulatory authorities greenlit the combo for later-line patients.

ARPA-H, part of HHS, has earmarked up to $142 million for 10 research projects building the tools, data, and infrastructure needed to tackle treatment resistance.

Data from a Phase I trial of Avmapki Fakzynja also supports the regimen's tolerability and suggests its potential activity in ...

The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

NEW YORK – Radiopharmaceutical company Nuclidium has raised $99 million in Series B financing to advance its copper-61 and copper-67 theranostics, the firm announced Thursday. The round was led by ...

NEW YORK – XyloCor Therapeutics on Thursday said it has treated the first patient with XC001 (encoberminogene rezmadenovec), its gene therapy for coronary artery disease and refractory angina, within ...

The drug, which Repare recently sidelined, has shown promising activity in a patient with ALT-positive melanoma that researchers want to study in others.